Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter D Senter

Showing results (61-70 of 83) with videos related to

Pageof 9
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2004
Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugateKevin J Hamblett, Peter D Senter, Dana F Chace, et al.
Bioconjugate Chemistry|March 16, 2006
Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT)Ralph F Alderson, Brian E Toki, Martin Roberge, et al.
Molecular Cancer Therapeutics|December 8, 2020
Novel Auristatins with High Bystander and Cytotoxic Activities in Drug Efflux-positive Tumor ModelsPhilip N Moquist, Tim D Bovee, Andrew B Waight, et al.
Nature Biotechnology|May 29, 2019
A coiled-coil masking domain for selective activation of therapeutic antibodiesVivian H Trang, Xinqun Zhang, Roma C Yumul, et al.
Cancer Research|November 18, 2008
A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivoDowdy Jackson, John Gooya, Shenlan Mao, et al.
The Journal of Biological Chemistry|February 18, 2006
Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugatesMay S Kung Sutherland, Russell J Sanderson, Kristine A Gordon, et al.
Cancer Chemotherapy and Pharmacology|June 2, 2007
Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMBVincent A Pollack, Enrique Alvarez, Kam Fai Tse, et al.
Chemmedchem|December 28, 2020
Improving Antibody-Tubulysin Conjugates through Linker Chemistry and Site-Specific ConjugationJoseph Z Hamilton, Thomas A Pires, Jamie A Mitchell, et al.
Molecular Cancer Therapeutics|January 8, 2017
Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug ConjugatesPatrick J Burke, Joseph Z Hamilton, Scott C Jeffrey, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2013
Development of orally active inhibitors of protein and cellular fucosylationNicole M Okeley, Stephen C Alley, Martha E Anderson, et al.
Pageof 9

Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2004
Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugateKevin J Hamblett, Peter D Senter, Dana F Chace, et al.
Bioconjugate Chemistry|March 16, 2006
Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT)Ralph F Alderson, Brian E Toki, Martin Roberge, et al.
Molecular Cancer Therapeutics|December 8, 2020
Novel Auristatins with High Bystander and Cytotoxic Activities in Drug Efflux-positive Tumor ModelsPhilip N Moquist, Tim D Bovee, Andrew B Waight, et al.
Nature Biotechnology|May 29, 2019
A coiled-coil masking domain for selective activation of therapeutic antibodiesVivian H Trang, Xinqun Zhang, Roma C Yumul, et al.
Cancer Research|November 18, 2008
A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivoDowdy Jackson, John Gooya, Shenlan Mao, et al.
The Journal of Biological Chemistry|February 18, 2006
Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugatesMay S Kung Sutherland, Russell J Sanderson, Kristine A Gordon, et al.
Cancer Chemotherapy and Pharmacology|June 2, 2007
Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMBVincent A Pollack, Enrique Alvarez, Kam Fai Tse, et al.
Chemmedchem|December 28, 2020
Improving Antibody-Tubulysin Conjugates through Linker Chemistry and Site-Specific ConjugationJoseph Z Hamilton, Thomas A Pires, Jamie A Mitchell, et al.
Molecular Cancer Therapeutics|January 8, 2017
Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug ConjugatesPatrick J Burke, Joseph Z Hamilton, Scott C Jeffrey, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2013
Development of orally active inhibitors of protein and cellular fucosylationNicole M Okeley, Stephen C Alley, Martha E Anderson, et al.
Pageof 9